about
The ENIGMA Consortium: large-scale collaborative analyses of neuroimaging and genetic dataRevolutionizing Alzheimer's disease and clinical trials through biomarkersImpact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014The impact of the Alzheimer's Disease Neuroimaging Initiative 2: What role do public-private partnerships have in pushing the boundaries of clinical and basic science research on Alzheimer's disease?UK publicly funded Clinical Trials Units supported a controlled access approach to share individual participant data but highlighted concernsProgress in developing common data elements for traumatic brain injury research: version two--the end of the beginningWhole-genome analyses of whole-brain data: working within an expanded search spaceDementia Prevention: optimizing the use of observational data for personal, clinical, and public health decision-makingCOSMIC (Cohort Studies of Memory in an International Consortium): an international consortium to identify risk and protective factors and biomarkers of cognitive ageing and dementia in diverse ethnic and sociocultural groupsHead-to-head comparison of two popular cortical thickness extraction algorithms: a cross-sectional and longitudinal study.Introduction to special issue: Overview of Alzheimer's Disease Neuroimaging Initiative.Discovering Alzheimer Genetic Biomarkers Using Bayesian Networks.The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target PopulationsRobustness of Automated Methods for Brain Volume Measurements across Different MRI Field Strengths.Structural and functional connectional fingerprints in mild cognitive impairment and Alzheimer's disease patients.Down syndrome and Alzheimer's disease: Common pathways, common goals.A strategy for developing new treatment paradigms for neuropsychiatric and neurocognitive symptoms in Alzheimer's disease.The impact of PICALM genetic variations on reserve capacity of posterior cingulate in AD continuum.STROKOG (stroke and cognition consortium): An international consortium to examine the epidemiology, diagnosis, and treatment of neurocognitive disorders in relation to cerebrovascular disease.Biomarkers in psychosis: an approach to early identification and individualized treatment.The Women's Healthy Ageing Project: fertile ground for investigation of healthy participants 'at risk' for dementia.Role of emerging neuroimaging modalities in patients with cognitive impairment: a review from the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012.Paths to Alzheimer's disease prevention: from modifiable risk factors to biomarker enrichment strategies.Biomarkers in Sporadic and Familial Alzheimer's Disease.Reflections on the Future of Pharmaceutical Public-Private Partnerships: From Input to Impact.Clinical and biomarker profiling of prodromal Alzheimer's disease in workpackage 5 of the Innovative Medicines Initiative PharmaCog project: a 'European ADNI study'.Military risk factors for Alzheimer's disease.Magnesium lithospermate B protects neurons from N-methyl-D-aspartic acid injury and attenuates kainic acid-induced neurodegeration in FVB mice.Insight into the Dissociation of Behavior from Histology in Synucleinopathies and in Related Neurodegenerative Diseases.Antihypertensive Treatment is associated with MRI-Derived Markers of Neurodegeneration and Impaired Cognition: A Propensity-Weighted Cohort Study.Validation of prognostic biomarker scores for predicting progression of dementia in patients with amnestic mild cognitive impairment.
P2860
Q24289484-FB0FD074-CFCB-4D66-AB97-246BF2A7D49FQ26744882-52C8E8BF-8054-4116-B500-0108441A994EQ26801629-98F420F0-7C7B-49AC-940B-7EE7113786E0Q26801634-6D756042-1678-47BC-8CE5-BB0EE8A5EBA0Q28601297-C8D20FEB-1AA0-4E8F-902D-F278E17C443AQ30637676-78A38757-2EC4-482A-B911-960471D3292CQ30827085-5B6BE9F4-8A1B-4988-94C0-ACA2E9E0D51CQ30978649-72C739B9-1428-4E05-AD9D-E34BC7556EC6Q35032898-5CB79E7D-A6A6-4962-B59F-B74CABA1D7ABQ35189641-D2F6E910-6D61-4446-8488-86E613EF14DDQ35700989-DEDFF896-A2A3-48FD-929E-8681FDBBE5CEQ36031308-EC15177F-76E1-478F-851E-B2546F4CC0C5Q36165011-552F50C6-4F4E-478B-9411-B933F1B34F87Q36178620-EF287C09-EC05-4D48-9F6B-7D53C3DE867BQ36319714-2F6CFF72-B629-493D-BDC3-69F6D1656A33Q36757252-42E4DBF6-D794-4860-BA5D-AE46830ECAD7Q36768052-F9299900-4218-430B-8FD6-4D7417A2E7B0Q36840915-FF0A6E77-9BBB-4BEC-BA6B-0FC497FACF90Q37600673-63F53CCC-8251-41FE-82B6-76F61A177FF2Q38170141-ACAD2A2D-5133-44BD-9DD2-5F4A1A8FD8ACQ38178374-3BF7EBDB-4AC2-4F91-ACB7-CE07A3EEF2FAQ38190687-7ECCD230-E402-4692-8B71-03B81468309DQ38344088-83AEB40A-DA25-471E-9922-73B04D51958BQ38592041-23AE74FE-9422-4C49-AE0C-7087A2C6BC7AQ38673910-A6AA4689-F91D-48E2-AA5C-B98DF51B7941Q40873275-CEF67939-6281-40F3-BD3B-30BDEFB1647BQ42606232-7FA29769-EF81-4046-AE79-A2E6EAF183C2Q45958879-3DDDACD8-CC56-48AB-B504-7B21FDFCF76DQ46571207-829F8A6D-D775-4871-9E68-2983240A1F7AQ48185429-6F9E1A62-B5F6-4D0B-8ADF-00BCA9A7F0E9Q49926296-4FEF795C-ACBE-49E8-B76B-70FEF9919F1D
P2860
description
2012 nî lūn-bûn
@nan
2012 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Worldwide Alzheimer's disease neuroimaging initiative
@ast
Worldwide Alzheimer's disease neuroimaging initiative
@en
Worldwide Alzheimer's disease neuroimaging initiative
@nl
type
label
Worldwide Alzheimer's disease neuroimaging initiative
@ast
Worldwide Alzheimer's disease neuroimaging initiative
@en
Worldwide Alzheimer's disease neuroimaging initiative
@nl
prefLabel
Worldwide Alzheimer's disease neuroimaging initiative
@ast
Worldwide Alzheimer's disease neuroimaging initiative
@en
Worldwide Alzheimer's disease neuroimaging initiative
@nl
P50
P921
P3181
P1476
Worldwide Alzheimer's disease neuroimaging initiative
@en
P2093
Lisa J Bain
P304
P3181
P356
10.1016/J.JALZ.2012.04.007
P407
P577
2012-07-01T00:00:00Z